Pacer Advisors
AKRO

Pacer Advisors’s Akero Therapeutics AKRO Stock Holding History

Pacer Advisors’s Portfolio AKRO Stock Details AKRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-688
Closed -$16.1K – 2558
2024
Q2 		$16.1K Sell
688
-677
-50% -$14.5K ﹤0.01% 3468
2024
Q1 		$34.5K Buy
+1,365
New +$32.8K ﹤0.01% 3317
2021
Q2 		– Sell
-1,034
Closed -$30K – 1402
2021
Q1 		$30K Sell
1,034
-216
-17% -$6.54K ﹤0.01% 1479
2020
Q4 		$32K Buy
+1,250
New +$34.8K ﹤0.01% 1456

Other funds holding AKRO

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
GA
General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Pacer Advisors's AKRO Position: Q3 2024 in Review

Pacer Advisors sold out of Akero Therapeutics (AKRO) in Q3 2024, closing a stake of 688 shares — an estimated $16.1K sold.

Pacer Advisors first reported a position in AKRO in Q4 2020 and held it in 4 quarters. The position peaked at $34.5K in Q1 2024. 168 funds tracked by Wall St. Rank hold AKRO as of Q3 2024.

  • Pacer Advisors reported no remaining Akero Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Pacer Advisors sold 688 Akero Therapeutics shares in Q3 2024, an estimated $16.1K.
  • Pacer Advisors first reported a position in Akero Therapeutics in Q4 2020 and held it in 4 quarters.
  • Pacer Advisors's Akero Therapeutics position peaked at $34.5K in Q1 2024.
  • 168 funds tracked by Wall St. Rank held Akero Therapeutics as of Q3 2024.

Based on Pacer Advisors's 13F filing for Q3 2024, filed 12 Nov 2024.